ArticleScientific reports2023
Usefulness of the BACES score in nontuberculous mycobacterial pulmonary disease for various clinical outcomes.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Immediate Treatment Versus Watchful Waiting in Mycobacterium avium Complex Pulmonary Disease: A Propensity Score Matched Analysis.Infectious diseases and therapy · 2026Article
- Predictors of treatment initiation in nontuberculous mycobacterial pulmonary disease: a real-life retrospective analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Observational
- Performance of the BACES model in a Dutch cohort with nontuberculous mycobacterial pulmonary disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Article
- Treatment and outcomes in patients with non-TB mycobacterial pulmonary disease: a single-centre study.IJTLD open · 2026Article
- Can the BACES score predict clinical outcomes in a Dutch cohort with nontuberculous mycobacterial pulmonary disease?ERJ open research · 2025Article
- BACES score: a predictor of health-related quality of life and associated factors in patients with nontuberculous mycobacterial pulmonary disease.Scientific reports · 2025Article
- Current and emerging treatment strategies forEwha medical journal · 2025Review
- Epidemiology of bronchiectasis at a single center in Japan: a retrospective cohort study.BMC pulmonary medicine · 2024Observational
- Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease.Scientific reports · 2024Article
- The Clinical Implications of Serum Carbohydrate Antigen 19-9 Levels in Patients with Nontuberculous Mycobacteria Pulmonary Disease.Journal of clinical medicine · 2023Article
- Spontaneous Cultural Conversion Rate ofJournal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A uniform prognostic marker is needed for nontuberculous mycobacterial pulmonary disease (NTM-PD) due to the diverse clinical course. We aimed to seek the utility of the BACES score, originally derived to predict all-cause mortality, for various outcomes. To calculate the BACES score, one point was given for each of the following factors: body mass index < 18.5 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.